Menu
Search
|

Menu

Close
X

Corbus Pharmaceuticals Holdings Inc CRBP.OQ (NASDAQ Stock Exchange Global Market)

5.35 USD
-0.10 (-1.83%)
As of Jul 20
chart
Previous Close 5.45
Open 5.55
Volume 50,678
3m Avg Volume 97,479
Today’s High 5.55
Today’s Low 5.35
52 Week High 9.85
52 Week Low 4.85
Shares Outstanding (mil) 50.22
Market Capitalization (mil) 371.63
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
2
FY16
2
FY15
1
EPS (USD)
FY18
-0.207
FY17
-0.644
FY16
-0.478
FY15
-0.286
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
134.55
5.73
Price to Book (MRQ)
vs sector
9.89
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.10
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-100.08
14.61
Return on Equity (TTM)
vs sector
-100.21
16.34

EXECUTIVE LEADERSHIP

Mark Tepper
President, Chief Scientific Officer, Since
Salary: $349,000.00
Bonus: $164,903.00
Yuval Cohen
Chief Executive Officer, Director, Since
Salary: $463,000.00
Bonus: $267,383.00
Sean Moran
Chief Financial Officer, Since
Salary: $335,000.00
Bonus: $140,700.00
Barbara White
Chief Medical Officer , Since 2014
Salary: $378,000.00
Bonus: $158,760.00
David Hochman
Director, Since 2013
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

100 River Ridge Dr
NORWOOD   MA   02062-5030

Phone: +1617.9630103

Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).

SPONSORED STORIES